Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction

7 Apr 2010

Abstract excerpt

PURPOSE: The prognostic and predictive relevance of epidermal growth factor receptor 2 (ERBB2) and topoisomerase II alpha (TOP2A) have long been a matter of debate. However, the correlation of DNA amplification, RNA levels, and protein expression and their prognostic role and association with anthracycline responses in node-negative breast cancer have not yet been evaluated. EXPERIMENTAL DESIGN: We first analyzed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Estrogen and related hormone effects
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20371687
DOI: 10.1158/1078-0432.ccr-09-2471

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and PredictionPMID 20371687Read ↗

HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.Semantic proximity Read ↗

Triple negative breast cancer - current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessmentSemantic proximity Read ↗

Amplification of the <i>TOP2A</i> gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samplesSemantic proximity Read ↗

Simultaneous Amplification of HER-2 (ERBB2) and Topoisomerase II&#945; (TOP2A) Genes - Molecular Basis for Combination Chemotherapy in CancerSemantic proximity Read ↗

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.Semantic proximity Read ↗

c-erbB2 and topoisomerase IIα protein expression independently predict poor survival in primary human breast cancer: a retrospective studySemantic proximity Read ↗

TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancerSemantic proximity Read ↗

The role of topoisomerase IIα and HER-2 in predicting sensitivity to anthracyclines in breast cancer patientsSemantic proximity Read ↗

The HER2 amplicon in breast cancer: Topoisomerase IIA and beyondSemantic proximity Read ↗

HER-2/neu and Topoisomerase IIα Gene Amplification and Protein Expression in Invasive Breast CarcinomasSemantic proximity Read ↗

HER2: Biology, Detection, and Clinical ImplicationsSemantic proximity Read ↗

Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.